Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome.
Age Factors
Aged
Aged, 80 and over
Case-Control Studies
Cross-Sectional Studies
Disease Progression
Female
Glucocorticoids
/ therapeutic use
Humans
Male
Menopause
/ physiology
Middle Aged
Osteoporosis
/ epidemiology
Osteoporotic Fractures
/ epidemiology
Registries
Sjogren's Syndrome
/ drug therapy
Spain
/ epidemiology
Bone remodeling
Osteoporosis
Osteoporotic fractures
Sjögren syndrome
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
17
02
2020
accepted:
31
05
2020
pubmed:
14
6
2020
medline:
12
5
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
This study aimed at determining socio-demographic and clinical factors of primary Sjögren syndrome (pSS) associated with osteoporosis (OP) and fragility fracture. SJOGRENSER is a cross-sectional study of patients with pSS, classified according to American European consensus criteria developed in 33 Spanish rheumatology departments. Epidemiological, clinical, serological and treatment data were collected and a descriptive analysis was conducted. Bivariate and multivariate analyses were performed using a binomial logistic regression to study the factors associated with OP and fragility fracture in pSS. 437 patients were included (95% women, with a median age of 58.6 years). 300 women were menopausal (76.4%). Prevalence of OP was 18.5% [in men (N = 21) this measured 19%]. A total of 37 fragility fractures were recorded. In the multivariate analysis, there was an association between OP and age: in the 51-64 age range (menopausal women), the OR measured 9.993 (95% CI 2301-43,399, p = 0.002); In the age > 64 years group, OR was 20.610 (4.679-90.774, p < 0.001); between OP and disease duration, OR was 1.046 (1.008-1085, p = 0.017); past treatment with corticosteroids, OR 2.548 (1.271-5.105, p = 0.008). Similarly, an association was found between fragility fractures and age: in the 51-64 age group, OR measured 5.068 (1.117-22,995, p = 0.035), age > 64 years, OR was 7.674 (1.675-35,151, p < 0.009); disease duration, OR 1.049 (CI 1.003-1097, p < 0.036) and the ESSDAI index, OR 1.080 (1.029-1134, p = 0.002). Patients with pSS can develop osteoporosis and fragility fractures over the course of the disease. Age, corticosteroids treatment and disease duration were associated with the development of OP. Disease duration and ESSDAI were associated with the development of fractures in patients with pSS.
Identifiants
pubmed: 32533289
doi: 10.1007/s00296-020-04615-3
pii: 10.1007/s00296-020-04615-3
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM